Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Telegram Restored on Apple App Store After Temporary Removal 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
WARREN, N.J., April 03, 2018 -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that Fabian Tenenbaum, President and Chief Executive Officer, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference, taking place April 8-10, 2018, in Monte Carlo, Monaco.
Bellerophon Presentation Details
Date: Tuesday, April 10, 2018
Time: 10:15 AM Central European Summer Time/4:15 AM Eastern Time
Location: Monte Carlo, Monaco - Le Meridien Beach Plaza Hotel
The presentation will be webcast live and archived for 90 days on Bellerophon's Investor Relations website at investors.bellerophon.com.
About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The Company is currently developing three product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system. The first is for the treatment of PAH, for which the Company has commenced Phase 3 clinical trials. The second is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third candidate is for the treatment of pulmonary hypertension associated with Interstitial Lung Disease (PH-ILD), both of which are in Phase 2 development. For more information, please visit www.bellerophon.com.
Contact
Bellerophon Therapeutics:
Fabian Tenenbaum, Chief Executive Officer
(908) 574-4767
LifeSci Advisors
Brian Ritchie
212-915-2578
[email protected]
